The period for CME/CE credit for this activity has expired.

Diabetes

Prospects for GLP-1 Receptor Agonists: When, Who, and How to Treat

INSTRUCTIONS

After completing the demographic questionnaire and the CME posttest and evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.


CME/CE Information

Activity Overview:
Patients with type 2 diabetes mellitus (T2DM) have diverse therapeutic needs depending on their stage of disease progression and underlying comorbidities, safety issues, and nonglycemic treatment goals. Short- and long-acting GLP-1 receptor agonists provide healthcare professionals (HCPs) with therapeutic options that address a number of these issues. This symposium will educate the audience on the differences and similarities among the GLP-1 receptor agonists, discuss their glycemic and nonglycemic effects, and identify approaches to increase success when implementing these therapies based on the new guidelines.

The audience will be given an opportunity to participate in an interdisciplinary collaboration with their colleagues and the faculty through an in-depth exploration of key issues and questions, including patient management, comorbidities, and safety considerations.

Intended Audience:
This activity is intended for physicians, nurses, nurse practitioners, physician assistants, certified diabetes educators, and other HCPs who care for patients with T2DM and manage the complications related to this disease.

Faculty:
John L. Leahy, MD — Chair

Professor of Medicine and Chief
Endocrinology, Diabetes and Metabolism Unit
University of Vermont College of Medicine
Burlington, Vermont

James R. Gavin III, MD, PhD
Clinical Professor of Medicine and Senior Health Advisor on Health Affairs
Emory University School of Medicine
Adjunct Professor of Medicine
Morehouse School of Medicine
Atlanta, Georgia

Geralyn Spollett, MSN, ANP-CS, CDE
Associate Director/Adult Nurse Practitioner
Yale Diabetes Center
Yale School of Medicine
New Haven, Connecticut

Agenda:

Welcome and Introduction
James R. Gavin III, MD, PhD

Talk 1
When: Glycemic Benefits of GLP-1 Receptor Agonists Along the Spectrum of Diabetes
James R. Gavin III, MD, PhD

Talk 2
Who: GLP-1 Receptor Agonists and Diverse Patient Needs
John L. Leahy, MD

Talk 3
How Do I Successfully Use These Agents for My Patients?
Geralyn Spollett, MSN, ANP-CS, CDE

Interactive Roundtable Question-and-Answer Discussion
Faculty

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Analyze data from clinical trials that demonstrate the effects of GLP-1 receptor agonists on glycemic control for patients at different stages of disease progression
  • Recognize nonglycemic effects of GLP-1 receptor agonists that may contribute to disease management in patients with type 2 diabetes
  • Evaluate safety and tolerability considerations with regard to GLP-1 receptor agonists
  • Identify approaches to promote successful implementation of therapy with GLP-1 receptor agonists

Learning Format:
This activity will feature lectures with questions through interactive online polling, whereby you can evaluate your answers against those of your colleagues. A wrap-up panel discussion led by the expert faculty will focus on current questions that are relevant to you in your clinical practice.

CME/CE Accreditation Statements:

ACCME       ANCC

For Physicians:
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IMNE designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For Nurses:
IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Committee on Accreditation.

IMNE designates this educational activity for 1.5 contact hours (0.15 CEUs). Accreditation by the ANCC's Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.

Faculty Disclosures:
In compliance with the ACCME and ANCC, it is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, educational partner staff, and CME/CE reviewers) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. IMNE also requires that faculty identify and reference off-label product or investigational uses of pharmaceutical agents and medical devices.

In accordance with the ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and IMNE policy, identification and resolution of conflict of interest have been made in the form of external peer review of educational content.

The following disclosures have been made:

Faculty:
John L. Leahy, MD — Chair

Formal Advisor: Daiichi Sankyo Co, Ltd; Merck & Co, Inc; sanofi-aventis
Research Activities: Takeda Pharmaceuticals North America, Inc
Consultant: Novo Nordisk Inc

Dr Leahy has disclosed that he anticipates discussing off-label or investigational uses of any products.

James R. Gavin III, MD, PhD
Formal Advisor: Abbott Laboratories; Amylin Pharmaceuticals, Inc;
Eli Lilly and Company; sanofi-aventis
Speakers Bureau: Eli Lilly and Company; Novo Nordisk Inc
Consultant: GlaxoSmithKline; sanofi-aventis
Commercial Interests: Amylin Pharmaceuticals, Inc

Dr Gavin has disclosed that he anticipates discussing off-label or investigational uses of any products.

Geralyn Spollett, MSN, ANP-CS, CDE
Formal Advisor: Eli Lilly and Company; GlaxoSmithKline; sanofi-aventis
Speakers Bureau: Eli Lilly and Company; Novo Nordisk Inc; sanofi-aventis

Ms Spollett has disclosed that she anticipates discussing off-label or investigational uses of any products.

CME Provider and Educational Partner Staff
All staff of IMNE in a position to influence content have filed statements of disclosure with the CE provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity. These disclosures are available for review by contacting Adelfo San Valentin at 404 443 1512 or adelfo.sanvalentin@imne.com.

Steve Weinman, RN
Executive Director
IMNE
Mr Weinman has nothing to disclose.

Adelfo San Valentin, MBA
Associate Director, CME
IMNE
Mr San Valentin has nothing to disclose.

Robin Devine, DO
Medical Writer
IMNE
Dr Devine has nothing to disclose.

Kim McFarland, PhD
Senior Medical Writer
IMNE
Stock Interests: Pfizer Inc; Procter & Gamble

Amy Carbonara
Director, Program Development
IMNE
Ms Carbonara has nothing to disclose.

Betsey King
Associate Director, Program Development
IMNE
Ms King has nothing to disclose.

CME and CE Reviewers:
Robert Hash, MD

Texas A&M Health Science Center
College of Medicine
College Station, Texas
Dr Hash has nothing to disclose.

Martin Quan, MD
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
Dr Quan has nothing to disclose.

Disclaimer:
This activity is designed for HCPs for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While IMNE makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his or her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

The content for this program was based on the live symposium that took place on February 5, 2010 at the ADA 57th Annual Advanced Postgraduate Course.

Commercial Support Acknowledgment:
This activity is supported by an educational grant from Novo Nordisk Inc.

Method of Participation:
To obtain CME credit, each participant should:

  • View the content presented
  • Answer all questions posed throughout the activity
  • Complete and submit the CME demographic and evaluation form
  • Print the online CME certificate

This activity should take approximately 1.5 hours to complete. The expiration date for this activity is December 31, 2011. No credit will be granted after this date.

Minimum System Requirements:
The following system requirements are recommended for the best presentation viewing experience:

  • Microsoft Windows 2000, Windows XP, Windows 2003, Windows Vista, or Macintosh OS X
  • Display resolution of 800 x 600 pixels or greater
  • Windows-compatible sound card
  • Microsoft Internet Explorer 6.0 SP1.
  • Windows Media Player 9.0
  • Broadband Internet connection (256 Kbps & above)

For a complete list of system requirements needed to view the webcast please click here (this link opens a pdf document). If you have any questions about viewing the webcast please contact us.

Date of Original Release: Friday, February 5, 2010 (satellite symposium)
Release Date: May 2010
Expiration Date: December 31, 2011

Estimated Time to Complete this Activity: 1.5 hours

ADA
Held in conjunction with the American Diabetes Association's 57th Advanced Postgraduate Course

IMNE
Sponsored by The Institute for Medical and Nursing Education, Inc.

ADA
Supported by an educational grant from Novo Nordisk Inc.

 I have read and understand the CME Information indexed above.

Webcast

CME Evaluation

    •  
    • CME Evaluation - This portion of the activity allows us to evaluate the types of healthcare professionals who are participating in the activity. This information will also be used to develop needs assessments for future educational programs on this topic. Thus, to the best of your ability, please respond with what you feel is the most accurate answer.
    •  
    • CME Posttest and Evaluation - This should be completed after the demographic questionnaire.
    •  
    •  
    •  
    • You can click on each section to preview this activity but you must be signed in to participate and receive CME credit. New to WebBasedCME.com? Click here to register.